Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Altea Therapeutics

BARDA Shake Up May Prompt Broad Review Of Politicization of Countermeasures Office

Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions. 

Coronavirus COVID-19 Politics

Novel Insulin Delivery Systems Pump New Life Into Diabetes Device Market

The market for insulin delivery devices is positioned to change significantly with several manufacturers gearing their products toward type 2 diabetics, who make up 90% to 95% of the diabetes patient pool in the US. These new, “pump-like” devices could offer the type 2 diabetes population better control in managing glucose levels, a solution the medical community has been seeking for a while.

Medical Device Consumer

Diabetes Device Market: Innovation Highlights Road to Growth

Despite the slumping economy, the diabetes market continues to be a very active area, with treatment-changing products recently launched or in late-stage development. Although no industry has been able to escape the effects of the US recession, and certain segments of the diabetes market have seen a decline in sales, other areas continue to move forward. Once the economy returns to healthier levels, the overall market is expected to see a renewal of growth. Meanwhile, an expanded emphasis on emerging international markets could help offset some of the sluggish numbers in the US and parts of Europe.

Medical Device

GLP-1 receptor agonists vie for diabetes market share

After enjoying almost five years of exclusivity, Lilly/Amylin's first-in-class antidiabetic GLP-1 receptor analogue Byetta (exenatide) has started to feel competition nipping at its heels. Asher Mullard investigates the future for this growing drug class and the next-generation therapeutics that are jockeying for position.

Metabolic Disorders Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Transdermal
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register